{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T16:29:57Z","timestamp":1770136197258,"version":"3.49.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.beha.2011.03.005","type":"journal-article","created":{"date-parts":[[2011,5,21]],"date-time":"2011-05-21T03:42:31Z","timestamp":1305949351000},"page":"279-293","source":"Crossref","is-referenced-by-count":28,"title":["Radioimmunotherapy in follicular lymphoma"],"prefix":"10.1016","volume":"24","author":[{"given":"Tim","family":"Illidge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Morschhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.beha.2011.03.005_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S1053-4296(00)80045-4","article-title":"Clinical radioimmunotherapy","volume":"10","author":"Knox","year":"2000","journal-title":"Semin Radiat Oncol"},{"issue":"6","key":"10.1016\/j.beha.2011.03.005_bib2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/MOH.0b013e3282efb17c","article-title":"Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies","volume":"14","author":"Park","year":"2007","journal-title":"Curr Opin Hematol"},{"issue":"9","key":"10.1016\/j.beha.2011.03.005_bib3","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Adams","year":"2005","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.beha.2011.03.005_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/1042819031000139666","article-title":"Monoclonal antibodies in the treatment of chronic lymphoid leukemias","volume":"45","author":"Robak","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"19","key":"10.1016\/j.beha.2011.03.005_bib5","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","article-title":"Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas","volume":"19","author":"Kaminski","year":"2001","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.005_bib6","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.1998.16.10.3246","article-title":"Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin\u2019s lymphoma","volume":"16","author":"DeNardo","year":"1998","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.beha.2011.03.005_bib7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood.V94.1.233.413a25_233_243","article-title":"The importance of antibody-specificity in determining successful radioimmunotherapy of B-cell lymphoma","volume":"94","author":"Illidge","year":"1999","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2011.03.005_bib8","first-page":"4906","article-title":"Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies","volume":"49","author":"Press","year":"1989","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.beha.2011.03.005_bib9","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V80.4.863.863","article-title":"Monoclonal antibody-based therapies of leukemia and lymphoma","volume":"80","author":"Grossbard","year":"1992","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.beha.2011.03.005_bib10","first-page":"5480","article-title":"CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts","volume":"63","author":"Chan","year":"2003","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.beha.2011.03.005_bib11","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1182\/blood-2003-01-0055","article-title":"Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia","volume":"102","author":"Jilani","year":"2003","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2011.03.005_bib12","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2011.03.005_bib13","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1182\/blood-2010-01-263533","article-title":"Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection","volume":"115","author":"Beers","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2011.03.005_bib14","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labelled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2011.03.005_bib15","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/ijc.2910560413","article-title":"Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2","volume":"56","author":"Shih","year":"1994","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.beha.2011.03.005_bib16","first-page":"350a","article-title":"Differential expression of CD22 in indolent and aggressive non-Hodgkin\u2019s lymphoma (NHL): implications for targeted therapy","volume":"100","author":"Cessano","year":"2002","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2011.03.005_bib17","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1586\/14737140.6.10.1341","article-title":"Epratuzumab in the therapy of oncological and immunological diseases","volume":"6","author":"Goldenberg","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.1016\/j.beha.2011.03.005_bib18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s002620050371","article-title":"Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22","volume":"44","author":"Sharkey","year":"1997","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.beha.2011.03.005_bib19","first-page":"77","article-title":"90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin\u2019s lymphoma","volume":"44","author":"Griffiths","year":"2003","journal-title":"J Nucl Med"},{"issue":"6 Suppl. 12","key":"10.1016\/j.beha.2011.03.005_bib20","first-page":"62","article-title":"Principles of radioimmunotherapy for hematologists and oncologists","volume":"27","author":"Press","year":"2000","journal-title":"Semin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2011.03.005_bib21","first-page":"2123","article-title":"Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells","volume":"56","author":"Press","year":"1996","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.beha.2011.03.005_bib22","first-page":"533","article-title":"67Cu-versus 131I-labeled Lym-1 antibody: comparative pharmacokinetics and dosimetry in patients with non-Hodgkin\u2019s lymphoma","volume":"5","author":"DeNardo","year":"1999","journal-title":"Clin Cancer Res."},{"issue":"8","key":"10.1016\/j.beha.2011.03.005_bib23","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1200\/JCO.2004.06.055","article-title":"Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"22","author":"Davies","year":"2004","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2011.03.005_bib24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","article-title":"131I-tositumomab therapy as initial treatment for follicular lymphoma","volume":"352","author":"Kaminski","year":"2005","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.beha.2011.03.005_bib25","first-page":"383","article-title":"Radioimmunotherapy of non-Hodgkin\u2019s lymphoma revisited","volume":"46","author":"Goldenberg","year":"2005","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.beha.2011.03.005_bib26","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.1996.14.4.1383","article-title":"Radioimmunotherapy: recent results and future directions","volume":"14","author":"Wilder","year":"1996","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.beha.2011.03.005_bib27","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/cncr.10304","article-title":"Rationales, evidence, and design considerations for fractionated radioimmunotherapy","volume":"94","author":"DeNardo","year":"2002","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.beha.2011.03.005_bib28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: a regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol Today"},{"issue":"1","key":"10.1016\/j.beha.2011.03.005_bib29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1172\/JCI110005","article-title":"A unique cell surface antigen identifying lymphoid malignancies of B cell origin","volume":"67","author":"Nadler","year":"1981","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.beha.2011.03.005_bib30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14737140.2.5.485","article-title":"Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma","volume":"2","author":"Grillo-Lopez","year":"2002","journal-title":"Expert Rev Anticancer Ther"},{"issue":"12","key":"10.1016\/j.beha.2011.03.005_bib31","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1200\/JCO.1999.17.12.3793","article-title":"Phase I\/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin\u2019s lymphoma","volume":"17","author":"Witzig","year":"1999","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.005_bib32","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1182\/blood.V99.12.4336","article-title":"Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial","volume":"99","author":"Wiseman","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2011.03.005_bib33","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1182\/blood-2003-11-3883","article-title":"Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1\/2 study","volume":"103","author":"Gordon","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2011.03.005_bib34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJM199308123290703","article-title":"Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody","volume":"329","author":"Kaminski","year":"1993","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.beha.2011.03.005_bib35","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.1996.14.7.1974","article-title":"Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma","volume":"14","author":"Kaminski","year":"1996","journal-title":"J Clin Oncol"},{"issue":"14S","key":"10.1016\/j.beha.2011.03.005_bib36","first-page":"615s","article-title":"The iodine 1\u2013131 tositumab therapeutic regimen: summary of safety in 995 patients with relapsed\/refractory low grade (LG) and transformed LG non-Hodgkin\u2019s lymphoma. (abs.6732)","volume":"22","author":"Gregory","year":"2004","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2011.03.005_bib37","first-page":"2000","article-title":"Radioimmunotherapy of non-Hodgkin\u2019s lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?","volume":"44","author":"Sharkey","year":"2003","journal-title":"J Nucl Med"},{"issue":"14","key":"10.1016\/j.beha.2011.03.005_bib38","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1158\/1078-0432.CCR-05-0172","article-title":"Dose-fractionated radioimmunotherapy in non-Hodgkin\u2019s lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab","volume":"11","author":"Linden","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"23","key":"10.1016\/j.beha.2011.03.005_bib39","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2009.27.7863","article-title":"High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I\/II study in non-Hodgkin\u2019s lymphoma","volume":"28","author":"Morschhauser","year":"2010","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2011.03.005_bib40","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"109","author":"Witzig","year":"2007","journal-title":"Cancer"},{"issue":"30","key":"10.1016\/j.beha.2011.03.005_bib41","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin\u2019s lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.beha.2011.03.005_bib42","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","article-title":"Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin\u2019s lymphoma","volume":"21","author":"Witzig","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2011.03.005_bib43","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","article-title":"Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab","volume":"23","author":"Horning","year":"2005","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.beha.2011.03.005_bib44","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.beha.2011.03.005_bib45","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1080\/10428190500376076","article-title":"Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin\u2019s lymphoma","volume":"47","author":"Emmanouilides","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"10.1016\/j.beha.2011.03.005_bib46","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1200\/JCO.2005.14.803","article-title":"Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.beha.2011.03.005_bib47","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1200\/JCO.2009.27.8325","article-title":"Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study","volume":"28","author":"Link","year":"2010","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.beha.2011.03.005_bib48","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","article-title":"Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911","volume":"24","author":"Press","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.005_bib49","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(08)70039-1","article-title":"Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ)","volume":"9","author":"Zinzani","year":"2008","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.beha.2011.03.005_bib50","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","article-title":"Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma","volume":"14","author":"Jacobs","year":"2008","journal-title":"Clin Cancer Res."},{"issue":"3","key":"10.1016\/j.beha.2011.03.005_bib51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3816\/CLM.2009.n.044","article-title":"Rituximab plus short-duration chemotherapy followed by yttrium-90 ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium","volume":"9","author":"Hainsworth","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"32","key":"10.1016\/j.beha.2011.03.005_bib52","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1016\/j.beha.2011.03.005_bib53","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1200\/JCO.2008.18.5447","article-title":"Evidence mounts for the efficacy of radioimmunotherapy for B-cell lymphomas","volume":"26","author":"Press","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.03.005_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3412.3412","article-title":"Radioimmunotherapy with 90Y-ibritumomab tiuxetan (Zevalin) as consolidation of first remission in patients with advanced stage follicular lymphoma: a \u2019real-time\u2019 MBR RQ-PCR analysis","volume":"110","author":"Goff","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2011.03.005_bib55","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2008-08-175653","article-title":"Phase 1\/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy","volume":"113","author":"Illidge","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.beha.2011.03.005_bib56","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2008-01-132142","article-title":"Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab","volume":"112","author":"Gopal","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2011.03.005_bib57","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.3319.3319","article-title":"Dosimetric analysis of 90Y-ibritumomab tiuxetan (Zevalin) given as consolidation of first remission in patients with advanced-stage follicular lymphoma in the international phase 3 trial First-Indolent Trial (FIT)","volume":"110","author":"Gondek","year":"2007","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2011.03.005_bib58","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.2967\/jnumed.109.067587","article-title":"Dosimetry of 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial","volume":"50","author":"Delaloye","year":"2009","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1016\/j.beha.2011.03.005_bib59","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/cncr.22066","article-title":"Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma","volume":"107","author":"Weigert","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.beha.2011.03.005_bib60","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ejca.2007.12.008","article-title":"Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice \u2013 report of a European workshop","volume":"44","author":"Zinzani","year":"2008","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.beha.2011.03.005_bib61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-006-0207-0","article-title":"Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma \u2013 role of radioimmunotherapy","volume":"86","author":"Dreyling","year":"2007","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.beha.2011.03.005_bib62","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2011.03.005_bib63","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1200\/jco.2010.28.15_suppl.8004","article-title":"Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy","volume":"28","author":"Salles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2011.03.005_bib64","doi-asserted-by":"crossref","first-page":"18S","DOI":"10.1200\/jco.2007.25.18_suppl.8033","article-title":"I131-tositumomab monotherapy as frontline treatment for follicular lymphoma:updated results after a median follow-up of 8 years","volume":"25","author":"Kaminski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.beha.2011.03.005_bib65","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.beha.2011.03.005_bib66","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","article-title":"Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma","volume":"26","author":"Marcus","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.beha.2011.03.005_bib67","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.beha.2011.03.005_bib68","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2001.19.9.2472","article-title":"Detection of chromosome abnormalities pre-high-dose treatment in patients developing therapy-related myelodysplasia and secondary acute myelogenous leukemia after treatment for non-Hodgkin\u2019s lymphoma","volume":"19","author":"Lillington","year":"2001","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.beha.2011.03.005_bib69","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3747\/co.v16i5.385","article-title":"I-Tositumomab in lymphoma","volume":"16","author":"Cheung","year":"2009","journal-title":"Curr Oncol"},{"issue":"11","key":"10.1016\/j.beha.2011.03.005_bib70","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2590.2590","article-title":"Long-term follow-up of the GELF86 French and Belgian trials: complete remission after first line treatment with conventional chemotherapy in newly diagnosed follicular lymphoma patients correlates with prolonged overall survival compared with partial remission","volume":"112","author":"Bachy","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.beha.2011.03.005_bib71","doi-asserted-by":"crossref","first-page":"147a","DOI":"10.1182\/blood.V108.11.485.485","article-title":"Analysis of the incidence of treatment-related myelodysplastic syndrome and acute myelogenous leukemia in registration and compassionate-use trials of ibritumomab tiuxetan radioimmunotherapy","volume":"108","author":"Czuczman","year":"2006","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.beha.2011.03.005_bib72","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1200\/JCO.2002.10.143","article-title":"Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin\u2019s lymphoma","volume":"20","author":"Ansell","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2011.03.005_bib73","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3816\/CLM.2004.n.028","article-title":"Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin\u2019s lymphoma: a review of the literature","volume":"5","author":"Ansell","year":"2004","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.beha.2011.03.005_bib74","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/asheducation-2004.1.203","article-title":"Low-grade lymphoma","author":"Winter","year":"2004","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"s2","key":"10.1016\/j.beha.2011.03.005_bib75","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1634\/theoncologist.2009-S2-41","article-title":"Radioimmunotherapy for stem cell transplantation in non-Hodgkin\u2019s lymphoma: in pursuit of a complete response","volume":"14","author":"Gisselbrecht","year":"2009","journal-title":"The Oncologist"},{"issue":"21","key":"10.1016\/j.beha.2011.03.005_bib76","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood.V116.21.594.594","article-title":"90Y-Ibritumomab Tiuxetan (Zevalin(r)) consolidation of first remission in advanced-stage follicular non-Hodgkin's lymphoma: updated results after a median follow-up of 66.2 months from the international, randomized, phase III first-line indolent trial (FIT) in 414 patients. The American Society of Hematology Orlando 2010","volume":"116","author":"Hagenbeek","year":"2010","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2011.03.005_bib77","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1182\/blood.V116.21.593.593","article-title":"MD6 G 90Yttrium Ibritumomab Tiuxetan as First Line Treatment for Follicular Lymphoma. First Results from an International Phase II Clinical Trial, The American Society of Hematology Orlando 2010","volume":"116","author":"Scholz","year":"2010","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692611000326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T21:38:48Z","timestamp":1637703528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692611000326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1521692611000326"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2011.03.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}